8-K
filed May 27, 2026, 4:07 PM ET
ticker ZNTL
CIK 0001725160
leadership
confidence high
sentiment neutral
materiality 0.25
Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members
Zentalis Pharmaceuticals, Inc.
- Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.
- Annual retainer of $45,000 for board service plus $7,500 for Compensation Committee membership.
- Granted RSUs covering 114,200 shares on May 26, 2026, vesting one-third annually over three years.
- After 6 months, eligible for annual equity grant of RSUs covering 0.08% of outstanding shares.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001725160-26-000049
- form_type
- 8-K
- ticker
- ZNTL
- cik
- 0001725160
- company_name
- Zentalis Pharmaceuticals, Inc.
- filed_at
- 2026-05-27T20:07:11+00:00
- discovered_at
- 2026-05-27T20:08:00.526322+00:00
- generated_at
- 2026-05-27T20:11:26.806584+00:00
- sec_items
- ["5.02"]
- event_type
- leadership
- sentiment
- neutral
- materiality_score
- 0.25
- calibrated_materiality_score
- 0.25
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001725160-26-000049
- json_url
- https://secwatch.observer/filing/0001725160-26-000049.json
- markdown_url
- https://secwatch.observer/filing/0001725160-26-000049.md
- text_url
- https://secwatch.observer/filing/0001725160-26-000049.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/0001725160-26-000049-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1725160/000172516026000049/zntl-20260522.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
DY
Dycom board reduced to nine; two directors retire after annual meeting
DYCOM INDUSTRIES INC
June 1, 2026, 8:04 AM ET
leadership
Items 5.02, 5.07
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
Ms. Laurie J. Thomsen did not stand for election at the 2026 Annual Meeting of Shareholders held on May 28, 2026 (the “2026 Annual Meeting”) and retired from the Board effective at the conclusion of the 2026 Annual Meeting.
Filing page
SEC filing
SBCF
Seacoast Banking director H. Gilbert Culbreth Jr. resigns from board effective June 15, 2026
SEACOAST BANKING CORP OF FLORIDA
May 29, 2026, 5:09 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
On May 27, 2026, H. Gilbert Culbreth, Jr. formally notified the Company of his decision to resign from the Board of Directors (the “Board”) of Seacoast Banking Corporation of Florida (“Seacoast” or the “Company”), effective June 15, 2026.
Filing page
SEC filing
ACAA
Averin Capital Acquisition Corp appoints Akiko Moni Miyashita to board
Averin Capital Acquisition Corp.
May 29, 2026, 4:30 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
On May 28, 2026, the board of directors (the “ Board ”) of Averin Capital Acquisition Corp. (the “ Company ”) appointed Akiko Moni Miyashita as a member of the Board, effective immediately.
Filing page
SEC filing
DKNG
DraftKings CFO Alan Ellingson becomes principal accounting officer; prior PAO remains CAO
DraftKings Inc.
May 29, 2026, 4:15 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
Erik Bradbury, the Company’s previous PAO, will remain in his position as the Company’s Chief Accounting Officer.
Filing page
SEC filing
BNTC
Benitec Biopharma appoints David Friedman to board; Megan Boston resigns as director but remains CFO
Benitec Biopharma Inc.
May 29, 2026, 4:10 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.
Filing page
SEC filing
JAZZ
Director Anne O'Riordan not standing for re-election at Jazz's 2026 annual meeting
Jazz Pharmaceuticals plc
May 29, 2026, 4:05 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.
Filing page
SEC filing
MSDL
Principal Accounting Officer Jonathan Frohlinger resigns effective May 26, 2026
Morgan Stanley Direct Lending Fund
May 29, 2026, 4:03 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
On May 26, 2026, Jonathan Frohlinger notified the Board of Directors of Morgan Stanley Direct Lending Fund (the “Company”) of his resignation as the Company’s Principal Accounting Officer, effective as of May 26, 2026.
Filing page
SEC filing
TTD
Samantha Jacobson becomes non-employee director; gets $50K cash + $290K equity grant
Trade Desk, Inc.
May 28, 2026, 8:08 PM ET
leadership
Items 5.02
same fact type: executive_change
same SEC item: 5.02
same event type: leadership
similar materiality
This filing
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director.
Comparable filing
the effective date of Ms. Jacobson’s resignation as an officer and employee of the Company
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.